Development and Validation of a Liquid Chromatography High‐Resolution Mass Spectrometry Method for Blood Desmopressin Quantification and Its Application in Hemophilia A Patients
Rapid Communications in Mass Spectrometry · 30.09.2025 · 39 (18)
DOI: 10.1002/rcm.10086 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Rapid Communications in Mass Spectrometry, online erschienen am 10.06.2025. Verfasst von Sophie Hodin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Saint-Etienne. Hauptthemen laut MEDLINE: Deamino Arginine Vasopressin, Hemophilia A, Mass Spectrometry. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Desmopressin (DDAVP), which indirectly increases Coagulation Factor VIII concentrations in the blood, is a common treatment for bleeding disorders such as von Willebrand disease or hemophilia A. However, DDAVP exhibits significant variability in response due to interindividual differences in pharmacokinetics. Consequently, exploring its pharmacokinetics is of primary importance to better understand the relationship between DDAVP administration and therapeutic outcomes. To that end, the measurement of DDAVP concentration is essential. This article describes the development and validation of a liquid chromatography method coupled with high‐resolution mass spectrometry detection for quantifying DDAVP in human plasma. After sample pretreatment involving protein precipitation followed by solid‐phase extraction, quantification was based on the four most intense isotopes, utilizing targeted single ion monitoring, with a method range of 20–2000 pg.mL −1 . For the four QC levels, accuracy and precision for both inter‐ and intra‐assay measurements were below 11.6% and 13.8%, respectively, meeting FDA recommendations. After validation, this method was applied to a cohort of 10 patients with a deficiency in Coagulation Factor VIII, who received 0.3 μg.kg −1 of desmopressin acetate. The mean volume of distribution at steady state was 18.8 L (CV% 26.7), the mean clearance was 7.8 L.h −1 (CV% 25.1), and the mean half‐life was 1.8 h (CV% 14.7). Offering valuable insights into the pharmacokinetics of DDAVP, this method will be useful for further studies and holds promise for optimizing treatment regimens in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Saint-Etienne.
- Laboratoire de Pharmacologie - Toxicologie, CHU de Saint-Etienne, Saint-Etienne, France.
- UR3801 PPF, Université de Reims Champagne Ardenne, Reims, France.
- CRH, CRC-MHC (Centre de Référence de l'Hémophilie, Centre de Ressource et de Compétence des Maladies Hémorragiques Constitutionnelles), University Hospital, Rennes, France.
- Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000, Rennes, France.
ORCID-Profile: Adrian Serban, Xavier Delavenne
Zitieren
APA
Hodin, S., Escal, J., Feliu, C., Pontis, A., Josset, L., Serban, A., Guillet, B., & Delavenne, X. (2025). Development and Validation of a Liquid Chromatography High‐Resolution Mass Spectrometry Method for Blood Desmopressin Quantification and Its Application in Hemophilia A Patients. Rapid Communications in Mass Spectrometry, 39(18). https://doi.org/10.1002/rcm.10086
Vancouver
Hodin S, Escal J, Feliu C, Pontis A, Josset L, Serban A, et al. Development and Validation of a Liquid Chromatography High‐Resolution Mass Spectrometry Method for Blood Desmopressin Quantification and Its Application in Hemophilia A Patients. Rapid Communications in Mass Spectrometry. 2025;39(18). doi:10.1002/rcm.10086
BibTeX
@article{Hodin2025,
author = {Hodin, Sophie and Escal, Jean and Feliu, Catherine and Pontis, Adeline and Josset, Laurie and Serban, Adrian and Guillet, Benoît and Delavenne, Xavier},
title = {Development and Validation of a Liquid Chromatography High‐Resolution Mass Spectrometry Method for Blood Desmopressin Quantification and Its Application in Hemophilia A Patients},
journal = {Rapid Communications in Mass Spectrometry},
year = {2025},
volume = {39},
number = {18},
doi = {10.1002/rcm.10086}
}
EUVIMED